A Phase 2 Open-Label, Multi-Center, Randomized, Controlled, Optimal Dose-Finding Study of DCC-UCB in Adults Receiving High Dose Chemotherapy for AML
Nohla Therapeutics is testing a hematopoietic stem cell and progenitor cell therapy called NLA101 to help patients suffering from neutropenia, a condition that leaves people susceptible to deadly infections, after receiving chemotherapy for acute myeloid leukemia (AML). The company is currently launching a Phase 2 trial to test this treatment in adult AML patients that have received high-dose chemotherapy.
Phase 2 open-label, multi-center, randomized, controlled, dose-finding study of safety and efficacy.
Evaluate effect on the rate of infections associated with Chemotherapy-Induced Neutropenia in AML patients and determine optimal dose of cell therapy.
News about this clinical trial:
- Nohla Therapeutics Awarded $6.9 Million Grant From The California Institute for Regenerative Medicine
- Nohla Therapeutics Initiates Global LAUNCH Phase 2 Trial of NLA101 in Patients with AML